Suppr超能文献

[过去20年肾移植的发展历程]

[The evolution of kidney transplantation over the last 20 years].

作者信息

Hourmant Maryvonne, Garandeau Claire

机构信息

CHU de Nantes, service de néphrologie-immunologie clinique, 44000 Nantes, France.

出版信息

Presse Med. 2011 Nov;40(11):1074-80. doi: 10.1016/j.lpm.2011.08.003. Epub 2011 Oct 2.

Abstract

Kidney transplantation is an efficient treatment of end stage renal disease, decreasing patient mortality by comparison with mortality in dialysis and improving patient quality of life. The number of patients living in France with a functioning transplant is almost as high as the number of patients on dialysis (33,000 versus 37,500 in 2009). The constant progress in immunosuppressive treatments has made graft survival improve. According to the "Agence de biomédecine", the national institution in charge of transplantation regulation and management, overall graft survival is 68% at 10 years but 80% for living donor transplantation. Transplantation indications have been extended with time to more difficult patients: retransplanted patients and elderly patients, to the point that age per se is no more a contraindication to transplantation. Increase in transplant activity has followed increase in kidney harvesting in marginal donors, called "extended criteria donors": older, hypertensive, having atherosclerotic pathologies. Kidney from these donors are attributed to recipients of similar age. With organ shortage, new sources of donors are proposed, non heart beating donors and living donors. Living donor transplantation is the best transplantation with the best results but it is insufficiently developed in France (8-10% of the total annual number of renal transplantations versus 30-50% in the Scandinavian and Anglo-Saxon countries). Extension of the definition of the living donor through the successive revisions of the Law of Bioethics should hopefully improved this situation.

摘要

肾移植是终末期肾病的一种有效治疗方法,与透析患者的死亡率相比,可降低患者死亡率,并提高患者生活质量。法国拥有功能正常移植肾的患者数量几乎与接受透析的患者数量一样多(2009年分别为33,000例和37,500例)。免疫抑制治疗的不断进步使移植肾的存活率得到提高。根据负责移植监管和管理的国家机构“生物医学局”的数据,移植肾的总体10年存活率为68%,但活体供肾移植的10年存活率为80%。随着时间的推移,移植适应症已扩大到更难治疗的患者:再次移植患者和老年患者,以至于年龄本身不再是移植的禁忌症。移植活动的增加伴随着边缘供体(即所谓的“扩展标准供体”)肾脏获取量的增加,这些供体年龄较大、患有高血压、有动脉粥样硬化病变。这些供体的肾脏被分配给年龄相仿的受者。由于器官短缺,人们提出了新的供体来源,即非心脏跳动供体和活体供体。活体供肾移植是效果最佳的移植方式,但在法国其发展不足(占每年肾移植总数的8 - 10%,而在斯堪的纳维亚和盎格鲁 - 撒克逊国家为30 - 50%)。通过《生物伦理法》的 successive revisions 不断扩大活体供体的定义有望改善这种情况。 (注:successive revisions 这里表述有误,应该是successive revision,表示“连续修订” )

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验